Diabetes mellitus remains a major global health concern, affecting an estimated 537 million adults worldwide, with India accounting for a significant proportion of cases.¹ Effective management depends not only on medication but also on regular monitoring of blood glucose levels. Self-monitoring helps guide treatment decisions, prevent complications, and improve long-term outcomes.
India is home to over 100 million individuals living with diabetes, highlighting the importance of accessible and reliable glucose monitoring strategies.¹
Two commonly used tools for monitoring are the glucometer and the continuous glucose monitor (CGM), a type of continuous glucose monitoring system. While both aim to track glucose levels, they differ in method, accuracy considerations, and clinical applications. These devices are commonly used for blood sugar monitoring at home.
A glucometer is a portable device used to measure blood glucose levels from a small capillary blood sample, usually obtained through a finger prick.
A drop of blood is placed on a disposable test strip inserted into the device. The glucometer analyzes the sample and provides a reading within seconds.
Provides a single point-in-time glucose value
Requires finger pricking for each measurement
Widely available and relatively affordable
Modern glucometers that meet international accuracy standards and require smaller blood sample volumes may improve ease of use and patient adherence in routine monitoring.
Glucometers are commonly used in routine home glucose monitoring, especially among individuals with type 2 diabetes.
A CGM is a type of continuous glucose monitoring system that continuously measures glucose levels in the interstitial fluid, which surrounds the body’s cells.
A small sensor is inserted under the skin, typically on the abdomen or arm. The sensor measures glucose levels at regular intervals and transmits data to a receiver or smartphone.
Real-time CGM (rtCGM): Continuously sends glucose readings and alerts
Intermittently scanned CGM (isCGM or flash): Requires scanning to view readings
Some newer CGM systems integrate with smartphone applications, allowing users to track glucose trends, receive alerts, and share data with healthcare providers in real time.
CGM systems provide not only glucose values but also trends and patterns over time, compared to traditional finger-prick testing.
| Feature | Glucometer | CGM |
|---|---|---|
| Measurement | Capillary blood glucose | Interstitial glucose |
| Frequency | Single readings | Continuous monitoring |
| Data | Individual values | Trends, graphs, alerts |
| Invasiveness | Multiple finger pricks | Sensor insertion every few days |
| Cost | Lower | Higher |
| Clinical insight | Limited | Comprehensive |
Glucometers are evaluated using international standards such as ISO 15197, which require most readings to fall within an acceptable range of laboratory values.² However, accuracy may be influenced by:
Improper technique
Poor strip quality
Environmental conditions
Devices that comply with ISO 15197 standards are generally recommended to ensure reliable readings in home settings.
CGM devices measure glucose in interstitial fluid, which results in a physiological delay compared to blood glucose levels. This delay is typically around 5 to 15 minutes.³
Accuracy is often expressed as Mean Absolute Relative Difference (MARD), with lower values indicating better accuracy.
In situations of rapidly changing glucose levels or suspected hypoglycemia, confirmatory testing with a capillary blood glucose measurement is recommended, as CGM readings may lag behind blood glucose values.
Affordable and accessible
Simple to operate
Suitable for routine monitoring
Requires repeated finger pricks
Does not show trends or fluctuations
Provides continuous data
Identifies trends and patterns
Alerts for hypoglycemia and hyperglycemia
Reduces frequency of finger pricks
Higher cost
Requires sensor replacement
Some systems may need calibration
Some CGM systems require periodic calibration with finger-stick glucose measurements, although newer models are factory calibrated.
Advances in sensor technology have improved the accuracy and usability of several CGM systems, making them increasingly practical for long-term glucose monitoring.
Individuals with type 2 diabetes on oral medications
Patients with stable glucose levels
Those requiring basic monitoring
Individuals with type 1 diabetes
Patients on insulin therapy
Those with frequent hypoglycemia
Patients requiring tighter glycemic control
Clinical guidelines increasingly support CGM use in individuals on intensive insulin regimens.⁴
Monitoring blood glucose plays a central role in achieving target HbA1c levels and reducing complications. While glucometers provide essential spot readings, CGM offers insights into:
Glycemic variability
Time in range
Nocturnal hypoglycemia
In addition to HbA1c, continuous glucose monitoring enables assessment of “time in range” (TIR), which reflects the percentage of time glucose levels remain within a target range, typically 70 to 180 mg/dL. Higher TIR has been associated with improved glycemic control and reduced risk of complications.
Studies have shown that the use of CGM in patients on intensive insulin therapy is associated with reductions in HbA1c levels and decreased incidence of hypoglycemia compared to traditional self-monitoring methods.⁴
These parameters are now recognized as important components of diabetes management.⁴
Glucometers are widely available and relatively inexpensive, making them accessible to a large population. In contrast, CGM systems involve higher upfront and recurring costs due to sensors, which may limit their use in resource-constrained settings.
When choosing between a glucometer and CGM, factors to consider include:
Frequency of monitoring required
Cost and affordability
Comfort with device usage
Clinical condition and treatment plan
Choosing devices with user-friendly interfaces, reliable accuracy standards, and accessible customer support can support consistent long-term use.
CGM readings should be interpreted with caution during acute illness, dehydration, or sensor-related issues, where discrepancies between interstitial and blood glucose levels may occur.
See more: FDA Warns: Faulty Glucose Monitors Linked to Possibly 7 Deaths and 736 Injuries
Advances in technology are improving the accuracy and usability of CGM systems. Research is also ongoing into non-invasive glucose monitoring methods, although these are not yet widely available for clinical use.
What is the main difference between a glucometer and a CGM?
A glucometer provides a single blood glucose reading at a specific time using a finger-prick sample, while a continuous glucose monitor tracks glucose levels continuously in interstitial fluid and provides trends, patterns, and alerts.
Which is more accurate, a glucometer or a CGM?
Glucometers measure capillary blood glucose and are considered reliable for spot readings when used correctly. CGM devices measure interstitial glucose and may show a slight delay compared to blood glucose, especially during rapid changes.
Is CGM suitable for people with type 2 diabetes?
Yes, CGM can be beneficial for some individuals with type 2 diabetes, especially those on insulin or those who need detailed glucose pattern analysis.
Can a CGM replace a glucometer completely?
A continuous glucose monitor can reduce the need for frequent finger-prick testing, but it may not completely replace a glucometer. In situations such as suspected hypoglycemia, rapidly changing glucose levels, or when readings do not match symptoms, confirmatory testing with a capillary blood glucose measurement is recommended.
Which is better, CGM or glucometer?
Neither device is universally better. A glucometer is suitable for basic, cost-effective monitoring, especially in stable type 2 diabetes. A CGM provides continuous data, trends, and alerts, making it more useful for individuals on insulin therapy or those requiring tighter glucose control. The choice depends on clinical needs, lifestyle, and affordability.
International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels, Belgium: 2021.
https://diabetesatlas.org/atlas/tenth-edition/
International Organization for Standardization. ISO 15197:2013 – In vitro diagnostic test systems.
https://www.iso.org/standard/54976.html
U.S. Food and Drug Administration. “Blood Glucose Monitoring Devices.” https://www.fda.gov/medical-devices/in-vitro-diagnostics/blood-glucose-monitoring-devices
American Diabetes Association. “Standards of Medical Care in Diabetes—2024.” Diabetes Care.
https://diabetesjournals.org/care/issue/47/Supplement_1
MSM